Advantages of robotic single-port hysterectomy compared to robotic multiport hysterectomy on clinical and aesthetic outcomes in patients with endometrial cancer
Robotic multiport (RMP) and single-site (RSS) hysterectomies are minimally invasive surgical techniques increasingly employed in the treatment of endometrial cancer. This study assesses whether RSS provides distinct therapeutic and aesthetic benefits compared to RMP, such as fewer and smaller incisions, which enhance cosmetic satisfaction and expedite postoperative recovery. A retrospective analysis of comparative research on RSS and RMP in endometrial cancer was performed utilizing PubMed and Google Scholar. Only publications in the English language from 2019 to 2025 were included. Studies were chosen based on their assessment of clinical results (e.g., operation duration, complications, hemorrhage, recovery time) and cosmetic outcomes (e.g., scar visibility, incision attributes, patient satisfaction). RSS correlated with reduced hospital durations, diminished postoperative discomfort, expedited recovery, and enhanced cosmetic outcomes attributable to fewer and smaller incisions. Both approaches exhibited similar safety profiles regarding blood loss, complication rates, and lymph node evaluation. RSS was associated with increased patient-reported satisfaction and enhanced postoperative physical performance. Nevertheless, characteristics such as BMI, comorbidities, and surgeon experience were evaluated inconsistently across trials, underscoring the lack of standardized reporting and the necessity for rigorously controlled research assessing these factors. RSS demonstrates enhanced aesthetic results and comparable clinical safety relative to RMP, rendering it a preferable choice for patients who prioritize recovery and cosmetic appearance. These findings can also guide tailored surgical planning and improve patient counseling in gynecologic oncology. Future randomized trials with a wider patient demographic and extended follow-up are crucial to validate these findings and evaluate their oncological longevity.